AGENUS INC Net Change in Cash
AGENUS INC (AGEN) reported Net Change in Cash of $15.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $32.00M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$21.95M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$23.25M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$13.86M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$39.36M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$35.71M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$101.56M.
- AGENUS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$113.26M, a 158.96% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.74M 10-Q · filed 2026-08-07 | ||||||
| 2026-03-31 | $32.00M 10-Q · filed 2026-05-11 | ||||||
| 2025-12-31 | -$39.36M 10-K · filed 2026-03-16 | ||||||
| 2025-09-30 | -$38.90M 10-Q · filed 2025-11-10 | ||||||
| 2025-06-30 | -$30.90M 10-Q · filed 2026-08-07 | ||||||
| 2025-03-31 | -$21.95M 10-Q · filed 2026-05-11 | ||||||
| 2024-12-31 | -$35.71M 10-K · filed 2026-03-16 | ||||||
| 2024-09-30 | -$31.36M 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | $17.58M 10-Q · filed 2025-08-11 | ||||||
| 2024-03-31 | -$23.25M 10-Q · filed 2025-05-12 | ||||||
| 2023-12-31 | -$101.56M 10-K · filed 2026-03-16 | ||||||
| 2023-09-30 | -$71.37M 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | -$35.47M 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | -$13.86M 10-Q · filed 2024-05-07 | ||||||
| 2022-12-31 | -$113.26M 10-K · filed 2025-03-17 | ||||||
| 2022-09-30 | -$83.58M 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | -$63.55M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | -$44.22M 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | $192.09M 10-K · filed 2024-03-14 | ||||||
| 2021-09-30 | $156.69M 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | -$26.29M 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | $19.53M 10-Q · filed 2022-05-10 | ||||||
| 2020-12-31 | $40.70M 10-K · filed 2023-03-16 | ||||||
| 2020-09-30 | $52.34M 10-Q · filed 2021-11-09 | ||||||
| 2020-06-30 | $17.36M 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | $30.48M 10-Q · filed 2021-05-07 | ||||||
| 2019-12-31 | $8.75M 10-K · filed 2022-03-01 | ||||||
| 2019-09-30 | $40.22M 10-Q · filed 2020-11-09 | ||||||
| 2019-06-30 | -$36.60M 10-Q · filed 2019-08-09 | $68.66M 10-Q · filed 2020-08-10 | |||||
| 2019-03-31 | $105.25M 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | $6.90M 10-K · filed 2019-03-18 | -$7.13M 10-K · filed 2021-03-16 | -$7.13M 10-K · filed 2019-03-18 | ||||
| 2018-09-30 | $3.00M 10-K · filed 2019-03-18 | -$14.02M 10-Q · filed 2019-11-07 | -$14.02M 10-Q · filed 2018-11-07 | ||||
| 2018-06-30 | -$9.20M 10-K · filed 2019-03-18 | -$17.02M 10-Q · filed 2019-08-09 | |||||
| 2018-03-31 | -$7.84M 10-Q · filed 2019-05-10 | -$7.80M 10-Q · filed 2018-11-07 | |||||
| 2017-12-31 | -$11.26M 10-K · filed 2020-03-16 | -$11.26M 10-K · filed 2019-03-18 | |||||
| 2017-09-30 | -$6.37M 10-Q · filed 2018-11-07 | ||||||
| 2016-12-31 | -$65.25M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |